NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

CompletedN/A

Sponsor: Pfizer

Conditions: Metastatic Breast Cancer

Interventions: Palbociclib + an aromatase inhibitor, Aromatase inhibitor

Countries: United States

A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor (AI) versus AI alone treatment in postmenopausal women or men with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States clinical practices.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Confirmed HR+/HER2- status after MBC diagnosis.
* Received palbociclib + AI or AI as first-line therapy

Exclusion Criteria:

* Evidence of prior treatment with other CDK4/6I, AI, tamoxifen, raloxifene, toremifene, or Fulvestrant for MBC
* First structured activity greater than 90 days after MBC diagnostic date
* Treatment with a CDK4/6 inhibitor as part of a clinical trial

Locations (1)

New York, New York, United States